- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.04. | Glucotrack veröffentlicht Peer-Review-Studie zur Langzeitstabilität seines Glukosesensors | 2 | Investing.com Deutsch | ||
| 14.04. | Glucotrack wandelt Schuldschein über 600.000 US-Dollar in Aktien um | 2 | Investing.com Deutsch | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 14.04. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Glucotrack GAAP EPS of -$31.22 | 1 | Seeking Alpha | ||
| 30.03. | GlucoTrack, Inc.: Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | 308 | GlobeNewswire (Europe) | Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents... ► Artikel lesen | |
| 30.03. | Glucotrack, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.03. | GlucoTrack Shares Surge 34% On FDA Submission Progress For Implantable Glucose Monitor | 1 | RTTNews | ||
| 27.03. | GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech | 1 | Benzinga.com | ||
| 27.03. | Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2 | 1 | MassDevice | ||
| 27.03. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Glucotrack plant FDA-Antrag für implantierbaren Blutzuckersensor | 1 | Investing.com Deutsch | ||
| 27.03. | Glucotrack plans FDA submission for implantable glucose monitor | 1 | Investing.com | ||
| 27.03. | Glucotrack, Inc.: Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones | 801 | GlobeNewswire (Europe) | RUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | Glucotrack, Inc.: Glucotrack to Present at LSI USA '26 Medtech Innovation Summit | 1 | GlobeNewswire (USA) | ||
| 29.01. | GlucoTrack Shares Slide 25% Despite New Patent Awards | - | RTTNews | ||
| 29.01. | Glucotrack picks up new patents for continuous blood glucose monitor | 1 | MassDevice | ||
| 29.01. | Glucotrack Stumbles Despite Winning Patent | - | Baystreet.ca | ||
| 29.01. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.01. | Glucotrack, Inc.: Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform | 229 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,100 | +0,27 % | EILMELDUNG bei Eckert&Ziegler: Hier baut sich gerade etwas Großes auf - So reagieren erfahrene Anleger jetzt | ||
| SERNOVA BIOTHERAPEUTICS | 0,109 | +0,93 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Closing of Recently Approved Financings | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,017 | -4,44 % | NuGen Medical Devices Inc.: NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology | Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| UNIDOC HEALTH | 0,055 | -8,31 % | UniDoc stellt Installation des H3 Health Cube in Italien fertig | - Der KI-gestützte Health Cube steht
ab sofort den Patienten im Dorf Guardia Perticara in der italienischen Region Basilikata zur Verfügung.
VANCOUVER, British Columbia... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: 150.000 Aktien gekauft - das ist der Grund! | Die Aktie von Sonoma Pharmaceuticals ist Zockern aus der sharedeals.de-Community seit Jahren bekannt. Mehrfach wurden dreistellige Kurs-Peaks innerhalb kürzester Zeit für herausragend lukrative Trading-Exits... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,600 | -3,03 % | Co-Diagnostics Reports Full Year 2025 Financial Results | Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures
Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform
Strengthening... ► Artikel lesen | |
| MEDIVOLVE | - | - | Medivolve Inc (2): OSC cites Bharti, Said for disclosure failures | ||
| QUIDELORTHO | 10,380 | -1,05 % | QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics | - Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics -- Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 169,25 | +0,89 % | Quest Diagnostics Raises 2026 EPS, Revenue Guidance | WASHINGTON (dpa-AFX) - Quest Diagnostics (DGX) said, for full year 2026, the company now expects adjusted diluted EPS in a range of $10.63 $10.83, revised from prior guidance range of $10.50... ► Artikel lesen | |
| VERU | 2,350 | 0,00 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| LIFEWARD | 4,805 | 0,00 % | Lifeward Ltd. - 8-K, Current Report | ||
| SENSEONICS | 6,150 | -0,81 % | Senseonics launches Eversense 365 year-long CGM in Europe | ||
| TEMPEST THERAPEUTICS | 1,695 | -1,45 % | Tempest Therapeutics: Tempest Reports Year End 2025 Financial Results and Provides Business Update | Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing... ► Artikel lesen |
GLUCOTRACK INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +3,68 % bei einem Aktienkurs von 0,739 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.